Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to -$15.2 million.

  • Assembly Biosciences' Free Cash Flow rose 45.26% to -$15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 34423.77%. This contributed to the annual value of -$51.1 million for FY2024, which is 32743.24% down from last year.
  • Latest data reveals that Assembly Biosciences reported Free Cash Flow of -$15.2 million as of Q3 2025, which was up 45.26% from -$16.8 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Free Cash Flow ranged from a high of $73.6 million in Q4 2023 and a low of -$36.4 million during Q1 2021
  • Moreover, its 5-year median value for Free Cash Flow was -$18.4 million (2024), whereas its average is -$14.0 million.
  • In the last 5 years, Assembly Biosciences' Free Cash Flow plummeted by 27736.24% in 2021 and then soared by 48213.36% in 2023.
  • Over the past 5 years, Assembly Biosciences' Free Cash Flow (Quarter) stood at -$19.4 million in 2021, then increased by 0.65% to -$19.3 million in 2022, then soared by 482.13% to $73.6 million in 2023, then tumbled by 100.55% to -$407000.0 in 2024, then tumbled by 3628.5% to -$15.2 million in 2025.
  • Its last three reported values are -$15.2 million in Q3 2025, -$16.8 million for Q2 2025, and -$23.4 million during Q1 2025.